heptapeptide raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
This page was last updated on 2026-03-24 and is reviewed periodically as new material appears.
Selank is a synthetic heptapeptide developed in Russia. Its sequence is Thr-Lys-Pro-Arg-Pro-Gly-Pro, a seven-residue chain built around the natural tetrapeptide tuftsin. Researchers at the Institute of Molecular Genetics of the Russian Academy of Sciences first described the compound in the mid-1990s. The design combined the tuftsin core with an added Pro-Gly-Pro tail, a modification intended to extend the molecule's stability in biological fluids. Published work on the peptide has appeared mainly in Russian-language journals.
Reported activity for Selank centers on anxiolytic and nootropic effects. Russian clinical reports describe use in anxiety and in cognitive or attention-related complaints. Most of this evidence comes from studies conducted by the same research groups that developed the peptide. Independent replication in other countries remains limited, and no major Western regulatory agency has approved the compound for any indication. The gap between local reports and external verification is a recurring point in discussions of the peptide.
Tuftsin, the parent structure, is a naturally occurring immunomodulatory tetrapeptide released from the Fc region of immunoglobulin G by spleen enzymes. Selank extends this four-residue sequence with three additional amino acids. The stated rationale is that the added tail slows enzymatic breakdown and may influence receptor interactions. How the full heptapeptide behaves at the molecular level is not firmly established, and proposed mechanisms often involve indirect modulation of neurotransmitter or immune signaling rather than a single defined target.
Proposed mechanisms center on modulation of the GABA system, but no single molecular target has been confirmed. Rodent studies report changes in GABA-A receptor expression and in the turnover of serotonin, dopamine, and norepinephrine in several brain regions. Increases in brain-derived neurotrophic factor and its receptor have also been described after repeated administration. These findings come largely from animal models, and the degree to which they describe human neurochemistry remains an open question. The mechanism is best characterized as multi-system and not fully resolved.
Pharmacokinetic data are limited. Like most short peptides, Selank is vulnerable to plasma and tissue peptidases, and its measured half-life in circulation is short, on a minutes scale. The Pro-Gly-Pro tail slows this degradation but does not eliminate it. Intranasal administration is the route described in most reports, with absorption through the nasal mucosa and a hypothesized path into the central nervous system that avoids the blood-brain barrier. Direct measurements of human brain exposure are unavailable, so distribution claims rest on inference from animal work.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic heptapeptide | Modeled on tuftsin |
| Amino acid sequence | Thr-Lys-Pro-Arg-Pro-Gly-Pro | Seven residues |
| Approximate molecular mass | Around 750 Da | Depends on counter-ion and hydration |
| Common forms | Lyophilized powder | Also described as aqueous solution |
| Primary origin of research | Russian laboratories | Mid-1990s onward |
The compound has a calculated molecular weight near 751.9 daltons and carries a net positive charge at physiological pH because of its arginine residue. It dissolves freely in water and in common aqueous buffers, and typically appears as a white or off-white lyophilized powder. The amide backbone makes the molecule susceptible to peptidases, which limits oral use and favors intranasal or parenteral routes. Nomenclature in the literature varies: the substance is also described by the sequence abbreviation TP-7 and by a Russian trade designation.
Regulatory status differs sharply by region. Selank holds a Russian marketing authorization, where it is supplied mainly as nasal drops, while authorities elsewhere have not approved it for medical use. Material sold internationally is therefore usually labeled as a research chemical rather than a medicine. Peer-reviewed publications come predominantly from Russian laboratories, and sample sizes are generally small. Whether the compound produces comparable effects under independent, well-controlled replication remains an open question that the broader literature has not settled.
Reported pharmacological effects center on reduced anxiety-like behavior in animal models and on measures of memory and learning. Proposed contributing mechanisms include modulation of GABAergic signaling, shifts in monoamine turnover, and changes in the activity of enzymes that degrade neuropeptides. Effects on the expression of genes linked to neuroplasticity have also been described. No single molecular target is widely accepted, and whether the behavioral findings arise from one pathway or several remains an open question.
Selank is a synthetic heptapeptide with the sequence Thr-Lys-Pro-Arg-Pro-Gly-Pro. It was designed as a stabilized analogue of tuftsin, a naturally occurring tetrapeptide fragment derived from the immunoglobulin heavy chain. The additional Pro-Gly-Pro segment at the carboxyl terminus is intended to slow enzymatic cleavage. The compound is usually described in the literature as a synthetic peptide with anxiolytic and cognitive-related activity, a label that reflects a research context rather than an approved therapeutic category.
Most published work on selank originates from a small number of research groups in the Russian Federation. A large share of that record appears in Russian-language journals, which limits access for readers who rely on English-indexed databases. Independent replication by laboratories outside the original research network is sparse in publicly available sources. This concentration of origin and language is a frequently noted feature when the compound is summarized in broader reviews of synthetic peptides.
Proposed mechanisms centre on modulation of the GABAergic system, with reports of altered expression of genes related to GABA-A receptor subunits and changed monoamine turnover. Some studies describe inhibition of enkephalinase, the enzyme that degrades endogenous enkephalins, which may prolong opioid peptide signalling. Effects on brain-derived neurotrophic factor and on cytokine expression have also been reported. These findings come largely from animal models and small human studies, and the precise primary target remains unresolved.
Published clinical evidence is limited. Most controlled trials were conducted in Russia, enrolled modest numbers of participants, and appeared in Russian-language journals, which restricts independent verification. Reported outcomes include lower anxiety scores, improved attention and memory measures, and changes in fatigue ratings. Reviews written in English note methodological limitations such as small samples and inconsistent endpoints. Whether the compound produces clinically meaningful benefit relative to established anxiolytics is therefore an open question rather than an established finding.
Mass spectral interpretation is the method employed to identify the chemical formula, characteristic fragment patterns and possible fragment ions from the mass spectra. Mass spectra is a plot of relative abundance against mass-to-charge ratio. It is commonly used for the identification of organic compounds from electron ionization mass spectrometry. Organic chemists obtain mass spectra of chemical compounds as part of structure elucidation and the analysis is part of many organic chemistry curricula.
In yeast and many bacteria, alcohol dehydrogenase plays an important part in fermentation: Pyruvate resulting from glycolysis is converted to acetaldehyde and carbon dioxide, and the acetaldehyde is then reduced to ethanol by an alcohol dehydrogenase called ADH1. The purpose of this latter step is the regeneration of NAD+, so that the energy-generating glycolysis can continue. Humans exploit this process to produce alcoholic beverages, by letting yeast ferment various fruits or grains. Yeast can produce and consume their own alcohol. The main alcohol dehydrogenase in yeast is larger than the human one, consisting of four rather than just two subunits. It also contains zinc at its catalytic site. Together with the zinc-containing alcohol dehydrogenases of animals and humans, these enzymes from yeasts and many bacteria form the family of "long-chain"-alcohol dehydrogenases. Brewer's yeast also has another alcohol dehydrogenase, ADH2, which evolved out of a duplicate version of the chromosome containing the ADH1 gene. ADH2 is used by the yeast to convert ethanol back into acetaldehyde, and it is expressed only when sugar concentration is low. Having these two enzymes allows yeast to produce alcohol when sugar is plentiful (and this alcohol then kills off competing microbes), and then continue with the oxidation of the alcohol once the sugar, and competition, is gone.
=== Polypeptide hormones, toxins, and antimicrobial peptides === Many hormones, toxins, inhibitors, or antimicrobial peptides interact specifically with transmembrane protein complexes. They can also accumulate at the lipid bilayer surface, prior to binding their protein targets. Such polypeptide ligands are often positively charged and interact electrostatically with anionic membranes. Some water-soluble proteins and peptides can also form transmembrane channels. They usually undergo oligomerization, significant conformational changes, and associate with membranes irreversibly. 3D structure of one such transmembrane channel, α-hemolysin, has been determined. In other cases, the experimental structure represents a water-soluble conformation that interacts with the lipid bilayer peripherally, although some of the channel-forming peptides are rather hydrophobic and therefore were studied by NMR spectroscopy in organic solvents or in the presence of micelles.
Sources: en.wikipedia.org
== Function == The human NDUFB2 gene codes for a subunit of Complex I of the respiratory chain, which transfers electrons from NADH to ubiquinone. However, NDUFB2 is an accessory subunit of the complex that is believed not to be involved in catalysis. Initially, NADH binds to Complex I and transfers two electrons to the isoalloxazine ring of the flavin mononucleotide (FMN) prosthetic arm to form FMNH2. The electrons are transferred through a series of iron-sulfur (Fe-S) clusters in the prosthetic arm and finally to coenzyme Q10 (CoQ), which is reduced to ubiquinol (CoQH2). The flow of electrons changes the redox state of the protein, resulting in a conformational change and pK shift of the ionizable side chain, which pumps four hydrogen ions out of the mitochondrial matrix.
In agriculture, Colombia is one of the five largest producers in the world of coffee, avocado and palm oil, and one of the 10 largest producers in the world of sugarcane, banana, pineapple and cocoa. The country also has considerable production of rice, potato and cassava. Although it is not the largest coffee producer in the world (Brazil claims that title), the country has been able to carry out, for decades, a global marketing campaign to add value to the country's product. Colombian palm oil production is one of the most sustainable on the planet, compared to the largest existing producers. Colombia is also among the 20 largest producers in the world of beef and chicken meat. Colombia is also the 2nd largest flower exporter in the world, after the Netherlands. Colombian agriculture emits 55% of Colombia's greenhouse gas emissions, mostly from deforestation, over-extensive cattle ranching, land grabbing, and illegal agriculture. Colombia is an important exporter of coal and petroleum – in 2020, more than 40% of the country's exports were based on these two products. In 2018 it was the 5th largest coal exporter in the world. In 2019, Colombia was the 20th largest petroleum producer in the world, with 791 thousand barrels/day, exporting a good part of its production – the country was the 19th largest oil exporter in the world in 2020.
Israel started evacuating the settlements located close to the border with Lebanon in October 2023 with more than 60 thousand evacuated by April 2024. In the early afternoon of 21 October, several rockets were fired from Lebanon toward the Shebaa Farms; there were no injuries. The IDF conducted a drone strike on the team of militants that launched the rockets. A short while later, anti-tank guided missiles were fired from Lebanon toward Margaliot and Hanita; two foreign workers were injured. The IDF conducted airstrikes against the missile teams. In the evening, another anti-tank guided missile was fired from Lebanon toward Bar'am. One IDF soldier was seriously injured and two others suffered minor injuries. The IDF responded with several airstrikes in southern Lebanon, some of which targeted other missile teams preparing attacks. The IDF conducted airstrikes against two Syrian military positions on 24 October in southwestern Syria, marking the first time the IDF publicly targeted the Syrian military since the Israel–Gaza war began. Hezbollah attacked 19 IDF military sites with missiles and artillery shells and fired one-way attack drones at an IDF position for the first time since the conflict began.
== Selected writings == Lévi, Éliphas (1841a). La Bible de la liberté [The Bible of Liberty]. Lévi, Éliphas (1841b). Doctrines religieuses et sociales [Religious and Social Doctrines]. Lévi, Éliphas (1841c). L'assomption de la femme [The Assumption of Woman]. Lévi, Éliphas (1844). La mère de Dieu [The Mother of God]. Lévi, Éliphas (1845). Le livre des larmes [The Book of Tears]. Lévi, Éliphas (1848). Le testament de la liberté [The Testament of Liberty]. Lévi, Éliphas (1854–1856). Dogme et Rituel de la Haute Magie [The Doctrine and Ritual of High Magic]. Includes material on alchemy Lévi, Éliphas (1860). Histoire de la magie [The History of Magic]. Lévi, Éliphas (1861). La clef des grands mystères [The Key to the Great Mysteries]. Lévi, Éliphas (1862). Fables et symboles [Stories and Symbols]. Lévi, Éliphas (1865). La science des esprits [The Science of Spirits]. Paris: Germer Baillière, Libraire-éditeur. Lévi, Éliphas (1868). Le grand arcane, ou l'occultisme dévoilé [The Great Secret, or Occultism Unveiled]. Lévi, Éliphas (1894). Le livre des splendeurs [The Book of Splendours]. Lévi, Éliphas (1895). Clefs majeures et clavicules de Salomon [Major Keys and Minor Keys of Solomon]. Lévi, Éliphas (1896). The Magical Ritual of the Sanctum Regnum.
Sources: en.wikipedia.org
CPC offers direct scale-up from analytical apparatuses (few milliliters) to industrial apparatuses (several liters) for fast batch-production. CPC seems particularly suited to accommodate aqueous two-phase solvent systems. Generally, CPC instruments can retain solvent systems that are not well-retained in a hydrodynamic instrument due to small differences in density between the phases. It has been very helpful for the development of CPC instrumentation to visualize the flow patterns which give rise to the mixing and settling in the CPC chamber with an asynchronous camera and a stroboscope triggered by the CPC rotor. The aforementioned hydrodynamic and hydrostatic instruments may be employed in a variety of ways, or modes of operation, in order to address the particular separation needs of the scientist. Many modes of operation have been devised to take advantage of the strengths and potentialities of the countercurrent chromatography technique. Generally, the following modes may be performed with commercially available instruments.
== History == Doxepin was discovered in Germany in 1963 and was introduced in the United States as an antidepressant in 1969. It was subsequently approved at very low doses in the United States for the treatment of insomnia in 2010.
=== Mechanism of action === As a antibody-drug conjugate (ADC), datopatomab deruxtecan binds to the carcinoma-associated antigen Trop-2, which is aberrantly expressed in some breast, colorectal, renal, and lung cancers. The drug-bound Trop2 protein undergoes receptor internalization, allowing the payload (i.e., the active anti-cancer drug) to be transported into the cell. It is transported into lysosomes. Inside the cell, it is split by selective cleaving of the tetrapeptide linker (Gly-Gly-Phe-Gly) by enzymes specific to tumor cells, such as cathepsins. It results in the release of exatecan, which acts on topoisomerase, an enzyme essential to DNA replication that controls coiling of the DNA helix, leading to DNA damage, cell replication arrest and, consequently, apoptosis. Then, exatecan is able to penetrate into neighboring cells, thereby causing a cascade of cell death. The minimum ihibitory concentration (MIC) of exatecan in vitro was shown to be equal to 0.31 μM. Exatecan is a derivative of camptothecin, a substance found in Camptotheca acuminata.
=== 2000s: Emergence of open-source AI === In the early 2000s open-source AI began to take off, with the release of more user-friendly foundational libraries and frameworks that were available for anyone to use and contribute to. OpenCV was released in 2000 with a variety of traditional AI algorithms like decision trees, k-Nearest Neighbors (kNN), Naive Bayes and Support Vector Machines (SVM).
The common adverse effects of bupropion with the greatest difference from placebo are dry mouth, nausea, constipation, insomnia, anxiety, tremor, and excessive sweating. Bupropion has the highest incidence of insomnia of all second-generation antidepressants, apart from desvenlafaxine. It is also associated with about 20% increased risk of headache. Bupropion raises blood pressure in some people. One study showed an average rise of 6 mm Hg in systolic blood pressure in 10% of patients. The prescribing information notes that hypertension, sometimes severe, is observed in some people taking bupropion, both with and without pre-existing hypertension. The safety of bupropion in people with cardiovascular conditions and its general cardiovascular safety profile remains unclear due to the lack of data. Bupropion has not been associated with QT prolongation at therapeutic doses but has been associated with QT prolongation in overdose. Seizure is a rare but serious adverse effect of bupropion. It is strongly dose-dependent: for the immediate release preparation, the seizure incidence is 0.4% at 300 to 450 mg per day; the incidence climbs almost 10-fold for the higher-than-recommended dose of 600 mg. For comparison, the incidence of unprovoked seizure in the general population is 0.07 to 0.09%, and the risk of seizure for a variety of other antidepressants is generally 0 to 0.5% at the recommended doses. Rare cases of liver toxicity leading to death or liver transplantation have been reported for bupropion.
Sources: en.wikipedia.org
Selank is a synthetic peptide made of seven amino acids. It is modeled on tuftsin, a natural tetrapeptide, with an added three-residue tail. It is not a small-molecule drug.
It originates from research in Russia, associated with the Institute of Molecular Genetics of the Russian Academy of Sciences. The first descriptions date to the mid-1990s. Most published studies come from Russian laboratories.
No, Selank itself does not occur naturally. Its backbone is based on tuftsin, which is produced in the body, but the seven-residue version is a synthetic construct. It is supplied as a manufactured peptide.
Reports describe effects on GABA-A receptor expression, monoamine turnover, and neurotrophic factor levels. These are proposed mechanisms drawn mainly from animal models. No single molecular target has been established.